Connor, Clark & Lunn Investment Management Ltd. Macrogenics Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Macrogenics Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 475,056 shares of MGNX stock, worth $1.52 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

475,056

Previous 418,282 13.57%

Holding current value

$1.52 Million

Previous $6.16 Million 67.22%

% of portfolio

0.01%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$3.31 - $18.51 $187,921 - $1.05 Million	56,774 Added 13.57%	475,056 $2.02 Million
Q1 2024 May 09, 2024	BUY	$9.77 - $21.47 $1.7 Million - $3.74 Million	174,086 Added 71.29%	418,282 $6.16 Million
Q4 2023 Feb 09, 2024	BUY	$4.48 - $10.11 $470,153 - $1.06 Million	104,945 Added 75.36%	244,196 $2.35 Million
Q3 2023 Nov 13, 2023	BUY	$4.48 - $6.19 $623,844 - $861,963	139,251 New	139,251 $648,000
Q3 2022 Nov 10, 2022	BUY	$3.01 - $5.22 $66,563 - $115,435	22,114 Added 10.02%	242,909 $840,000
Q2 2022 Aug 05, 2022	BUY	$2.25 - $9.99 $394,519 - $1.75 Million	175,342 Added 385.77%	220,795 $651,000
Q1 2022 May 12, 2022	BUY	$8.12 - $16.9 $45,934 - $95,603	5,657 Added 14.21%	45,453 $400,000
Q4 2021 Feb 10, 2022	BUY	$15.91 - $21.88 $56,130 - $77,192	3,528 Added 9.73%	39,796 $639,000
Q3 2021 Nov 12, 2021	BUY	$19.74 - $28.7 $715,930 - $1.04 Million	36,268 New	36,268 $759,000
Q2 2020 Aug 13, 2020	SELL	$5.2 - $29.12 $341,218 - $1.91 Million	-65,619 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$4.28 - $12.11 $154,054 - $435,887	35,994 Added 121.5%	65,619 $381,000
Q4 2019 Feb 12, 2020	BUY	$7.95 - $12.27 $235,518 - $363,498	29,625 New	29,625 $322,000

Others Institutions Holding MGNX

# of Institutions

154

Shares Held

60.6M

Call Options Held

218K

Put Options Held

259K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $196M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Macrogenics Inc Transaction History